Shares of Life Technologies (NAS: LIFE) hit a 52-week high last week. Let's look at what's behind this stock's recent movements to try to better understand what might happen in its future.

How it got here
It's been a year of divergence for genomics companies. The sector's two leading lights, Life Tech and Illumina (NAS: ILMN) , have both posted solid gains in the past 52 weeks, while Sequenom and Complete Genomics (NAS: GNOM) have slipped. Pacific Biosciences (NAS: PACB) , after jumping earlier this year on buyout rumors driven by Illumina's hostile-takeover battle, has slipped to join the second-stringers with deep losses:

LIFE Total Return Price Chart


LIFE Total Return Price data by YCharts.

Life Tech's had more stable gains than Illumina, and it has been buoyed lately by a string of good news. The company started shipping its Ion Proton sequencers last month, making good on the promise of sequencing an entire human genome for just $1,000. More than 100 Ion Protons had been readied for the initial shipment, and Life Tech reported strong demand for the new machines in its announcement.

Life Tech also announced several partnerships in September, including one with Bristol-Myers Squibb  (NYS: BMY) to develop companion diagnostics for more personalized medicines; one with biotech start-up Pathogenica to market hospital-infection detection kits; and one with genomic analysis start-up CollabRx to commercialize cancer-diagnostics sequencing. It also launched advanced DNA-testing kits for criminal forensics labs and opened a Chinese manufacturing facility to produce those kits.

September was indeed a busy month, and October has started off with a bang as well. Life Tech just announced the acquisition of Compendia Bioscience this week. The deal further extends Life Tech's cancer screening capabilities and also enhances the company's personalized-medicine efforts.

Do all these moves portend greater gains, or are investors bidding up shares more on hope than on hard data? Let's dig into the numbers of Life Tech and its peers to find out.

What you need to know
Although Life Tech's stock isn't the cheapest on the market, it appears by far the most reasonably priced in its sector. The company has maintained a much lower P/E than Illumina thanks in part to a better net margin, and its forward growth expectations, though not eye-popping, are respectable, especially in light of anemic expectations for some of its competitors:

Company

P/E Ratio

Price to Levered Free Cash Flow 

Net Margin (TTM)

Projected Growth Rate (2013) 

Life Technologies

20.8

17.4

11.6%

8.9%

Illumina

84.4

24.0

7.8%

12.7%

Sequenom

NM

NM

(152%)

41.5%

Complete Genomics

NM

NM

(431.1%)

6.7%

Pacific Biosciences

NM

NM

(253.6%)

4.6%

Source: Yahoo! Finance. NM = not material due to negative results.

The Ion Proton machines discussed earlier are going to be major focal points of investor interest going forward. Affordable genome sequencing opens up a host of medical possibilities that have never before been possible, and at $1,000 per genome, Life Tech's machines pose serious competition to industry leader Illumina -- if its sequences are accurate enough.

Life Tech has competition on multiple genome-sequencing fronts, including small-scale portable machines from genomics start-ups, as well as Illumina's and Pacific Biosciences' machines. Obamacare could be both bane and boon to the entire sector over time, as my fellow Fool Sean Williams noted after the Supreme Court upheld the law. I'm more of the opinion that wider health coverage, combined with plummeting sequencing costs, could create an investing bubble not unlike that of the dot-com era, as software developers work with drugmakers to unlock, understand, and exploit the mysteries of the genome. Life Tech has the largest R&D budget in the sector, which is no small advantage in this high-speed race for better, cheaper, faster sequencing.

What's next?
Investors needn't worry that Life Tech is bubbling up to stratospheric valuations. The company's P/E is below its two-year average, and a strong third and fourth quarter could easily push that number below 20 and into "screaming buy" territory, even as the stock continues to rise. The Motley Fool's CAPS community thinks highly of Life Technologies, granting it a perfect five-star rating. Only 4% of our CAPS players expect the company to underperform in the future.

If you're looking for other world-changing technologies to invest in, the Fool has three companies you might love. They're in the middle of a "new industrial revolution," which is changing the shape of manufacturing just as surely as genomics is changing medicine. Find out everything in our highly-requested free report -- click here for the information you need, at no cost.

The article Life Technologies Is Still Best in Class originally appeared on Fool.com.

Fool contributor Alex Planes holds no financial position in any company mentioned here. Add him on Google+ or follow him on Twitter @TMFBiggles for more news and insights. Motley Fool newsletter services have recommended buying shares of Illumina and Pacific Biosciences of California. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Small Cap Investing

Learn now to invest in small companies the right way.

View Course »

Investing in Startups

The lucrative and risky world of startups.

View Course »

Add a Comment

*0 / 3000 Character Maximum

1 Comment

Filter by:
scbaker

Well, I wouldn't say Ion Torrent is quite yet " making good on the promise of sequencing an entire human genome for just $1,000". They've just launched the PI chip which they say can generate 10Gb of sequence (but we haven't seen independent verification of this just yet). It won't be until the PII chip is released next year (March is the target) until they say they'll have the $1000 genome. And even then they may not have it as they've dropped the PII specs to 20X coverage of the human genome (30-40X is generally considered 'full coverage'). We've got all the specs for Ion Torrent (as well as all other NGS technologies) listed in our NGS Knowledge Bank at http://www.blueseq.com/

October 08 2012 at 9:22 PM Report abuse rate up rate down Reply